Literature DB >> 13549737

Persistence of circulating antibodies in human subjects immunized with dextran, levan and blood group substances.

P Z ALLEN, E A KABAT.   

Abstract

Entities:  

Keywords:  ANTIBODIES; POLYSACCHARIDES

Mesh：

Substances：

Year:  1958        PMID： 13549737

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  7 in total

1.  Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells.

Authors:  Jeremy B Foote; Tamer I Mahmoud; Andre M Vale; John F Kearney
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

2.  Studies on human antibodies. 8. Properties and association constants of human antibodies to blood group A substance purified with insoluble specific adsorbents and fractionally fluted with mono- and oligosaccharide.

Authors:  C Moreno; E A Kabat
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

3.  Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.

Authors:  M Deshaw; L A Pirofski
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

4.  Specific fractionation of a population of antidextran molecules with combining sites of various sizes.

Authors:  S F SCHLOSSMAN; E A KABAT
Journal:  J Exp Med       Date:  1962-10-01       Impact factor: 14.307

5.  STUDIES ON HUMAN ANTIBODIES. I. STARCH GEL ELECTROPHORESIS OF THE DISSOCIATED POLYPEPTIDE CHAINS.

Authors:  G M EDELMAN; E A KABAT
Journal:  J Exp Med       Date:  1964-03-01       Impact factor: 14.307

6.  STUDIES ON HUMAN ANTIBODIES. II. DISTRIBUTION OF GENETIC FACTORS.

Authors:  J C ALLLEN; H G KUNKEL; E A KABAT
Journal:  J Exp Med       Date:  1964-03-01       Impact factor: 14.307

7.  Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers.

Authors:  W J Yount; M M Dorner; H G Kunkel; E A Kabat
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.